Autopsy report · NCT00380835

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

“Study Never Initiated”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Celgene Corporation

Sponsor type

Industry

Conditions

Metastatic Breast Cancer

Interventions

Amrubicin

Participants

66 (planned, not actual)

Sites

28

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.